Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC)

被引：0
作者：
Reck, M. [1 ]
Frickhofen, N. [2 ]
Gatzemeier, U. [1 ]
Fuhr, H. G. [2 ]
Lanzalone, S. [3 ]
Wang, E. [4 ]
Chao, R. [4 ]
Felip, E. [5 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] Dr Horst Schmidt Klin, Wiesbaden, Germany
[3] Pfizer Italia, Milan, Italy
[4] Pfizer Inc, Global Res & Dev, La Jolla, CA USA
[5] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71435-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6607
引用
收藏
页码：390 / 390
页数：1
相关论文
共 50 条
[21]   Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results [J].
Steward, WP ;
Dunlop, DJ ;
Dabouis, G ;
Lacroix, H ;
Talbot, D .
SEMINARS IN ONCOLOGY, 1996, 23 (05) :43-47
[22]   Phase II study of Gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer [J].
Mohedano, N ;
Medina, MB ;
Sanchez, P ;
Jaen, A ;
Gonzalez, E ;
Porras, I ;
Fernandez, M ;
Lozano, A .
ANNALS OF ONCOLOGY, 1998, 9 :90-90
[23]   Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma [J].
D. Ross Camidge ;
Normand Blais ;
Derek J. Jonker ;
Denis Soulières ;
Robert C. Doebele ;
Ana Ruiz-Garcia ;
Aron Thall ;
Ke Zhang ;
Scott A. Laurie ;
Richard C. Chao ;
Laura Q. Chow .
Cancer Chemotherapy and Pharmacology, 2013, 71 :307-319
[24]   Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma [J].
Camidge, D. Ross ;
Blais, Normand ;
Jonker, Derek J. ;
Soulieres, Denis ;
Doebele, Robert C. ;
Ruiz-Garcia, Ana ;
Thall, Aron ;
Zhang, Ke ;
Laurie, Scott A. ;
Chao, Richard C. ;
Chow, Laura Q. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) :307-319
[25]   Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results of an ongoing phase I/II study [J].
Steward, WP ;
Dunlop, DJ ;
Cameron, C ;
Talbot, DC ;
Kleisbauer, JP ;
Thomas, P ;
Guerin, JC ;
Perol, M ;
Sanson, C ;
Dabouis, G ;
Lacroix, H .
ANTI-CANCER DRUGS, 1995, 6 :33-37
[26]   Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer [J].
Shepherd, FA ;
Latreille, J ;
Paul, K ;
Eisenhauer, E .
SEMINARS IN ONCOLOGY, 1996, 23 (06) :84-90
[27]   Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study [J].
Spira, Alexander I. ;
Cho, Byoung Chul ;
Kim, Tae Min ;
Kim, Sang-We ;
Xia, Bing ;
Artis, Eunice ;
Dobbs, Jessica ;
Baudelet, Christine ;
Baig, Mahadi ;
Sendur, Mehmet Ali Nahit .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28]   PHASE I DOSE-ESCALATION STUDY OF VORINOSTAT COMBINED WITH GEMCITABINE AND PLATINUM AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER [J].
Descourt, R. ;
Zalcman, G. ;
Moro-Sibilot, D. ;
Tredaniel, J. ;
Misset, J. ;
Gachard, E. ;
Garcia-Vargas, J. ;
Reiser, D. ;
Roben, E. ;
Rizvi, S. .
ANNALS OF ONCOLOGY, 2008, 19 :111-111
[29]   Divided doses of cisplatin in combination with gemcitabine for patients with advanced non-small cell lung cancer (NSCLC). [J].
Demirkazik, A ;
Yalcin, B ;
Akbulut, H ;
Buyukcelik, A ;
Cay, F ;
Utkan, G ;
Icli, F .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :702S-702S
[30]   Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer [J].
Esteban, E ;
Fra, J ;
Sala, M ;
Carrasco, J ;
Corral, N ;
Vieitez, JM ;
Estrada, E ;
Palacio, I ;
Buesa, JM ;
Lacave, AJ .
INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) :317-326
12345